Sitc 2025 Ak132. Sitc Conference 2025 Hedda Eachelle 8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926.HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. The binding activity of AK132, anti-CLDN18.2 and AK117 to CHO-K1 cells which transfected with CLDN18.2 and CD47 were detected by FACS
SITC Campus Leading Higher Education Institute in Sri Lanka from sitc.lk
A similar approach is being pursued by Akeso, which in addition to the MAb ligufalimab recently took into phase 1 AK132, an anti-Claudin18.2 x CD47 MAb Results AK132 could bind to human CD47 and CLDN18.2 on CD47 + CLDN18.2 + cells, with same activity relative to its parental mAbs, AK117 (anti-CD47 mAb) and anti-CLDN18.2
SITC Campus Leading Higher Education Institute in Sri Lanka
The binding activity of AK132, anti-CLDN18.2 and AK117 to CHO-K1 cells which transfected with CLDN18.2 and CD47 were detected by FACS Results AK132 could bind to human CD47 and CLDN18.2 on CD47 + CLDN18.2 + cells, with same activity relative to its parental mAbs, AK117 (anti-CD47 mAb) and anti-CLDN18.2 The binding activity of AK132, anti-CLDN18.2 and AK117 to CHO-K1 cells which transfected with CLDN18.2 and CD47 were detected by FACS
Home SITC 2025. 8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926.HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. The SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiti.
Home SITC 2025. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. The 2025 SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing these novel therapies to patients in need.